Menu
Currency
GWAS Study

Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells.

Li J, Jørgensen SF, Maggadottir SM et al.

25891430 PubMed ID
GWAS Study Type
11777 Participants
34 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

LJ
Li J
JS
Jørgensen SF
MS
Maggadottir SM
BM
Bakay M
WK
Warnatz K
GJ
Glessner J
PR
Pandey R
SU
Salzer U
SR
Schmidt RE
PE
Perez E
RE
Resnick E
GS
Goldacker S
BM
Buchta M
WT
Witte T
PL
Padyukov L
VV
Videm V
FT
Folseraas T
AF
Atschekzei F
EJ
Elder JT
NR
Nair RP
WJ
Winkelmann J
GC
Gieger C
NM
Nöthen MM
BC
Büning C
BS
Brand S
SK
Sullivan KE
OJ
Orange JS
FB
Fevang B
SS
Schreiber S
LW
Lieb W
AP
Aukrust P
CH
Chapel H
CC
Cunningham-Rundles C
FA
Franke A
KT
Karlsen TH
GB
Grimbacher B
HH
Hakonarson H
HL
Hammarström L
EE
Ellinghaus E
Chapter II

Abstract

Summary of the research findings

Common variable immunodeficiency disorder (CVID) is the most common symptomatic primary immunodeficiency in adults, characterized by B-cell abnormalities and inadequate antibody response. CVID patients have considerable autoimmune comorbidity and we therefore hypothesized that genetic susceptibility to CVID may overlap with autoimmune disorders. Here, in the largest genetic study performed in CVID to date, we compare 778 CVID cases with 10,999 controls across 123,127 single-nucleotide polymorphisms (SNPs) on the Immunochip. We identify the first non-HLA genome-wide significant risk locus at CLEC16A (rs17806056, P=2.0 × 10(-9)) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome 6p21 (rs1049225, P=4.8 × 10(-16)). Clec16a knockdown (KD) mice showed reduced number of B cells and elevated IgM levels compared with controls, suggesting that CLEC16A may be involved in immune regulatory pathways of relevance to CVID. In conclusion, the CLEC16A associations in CVID represent the first robust evidence of non-HLA associations in this immunodeficiency condition.

778 European ancestry cases, 10,999 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

11777
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Sweden, U.S., Norway, U.K., Germany
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.